Abstract
B-cell chronic lymphocytic leukaemia (B-CLL) cannot be cured by conventional chemotherapy, therefore, toxin-linked therapeutic monoclonal antibodies (mAbs) are increasingly examined for their potential to improve clinical outcome. The current study aimed to identify mAbs that were internalized by the B-CLL cells of 14 patients, using both flow cytometry and confocal laser scanning microscopy. Anti-CD5, CD22 and CD40 mAbs were effectively taken up by B-CLL cells, whereas mAbs against CD19, CD20, CD23 and CD45 were not. This study may form a basis for further research to identify antibodies that may serve as carriers for toxins to treat B-CLL.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / immunology*
-
Antigens, CD / immunology
-
Antigens, CD19 / immunology
-
Antigens, CD20 / immunology
-
Antigens, Differentiation, B-Lymphocyte / immunology
-
B-Lymphocytes / physiology*
-
CD40 Antigens / immunology
-
CD5 Antigens / immunology
-
Cell Adhesion Molecules*
-
Drug Carriers
-
Endocytosis / physiology*
-
Flow Cytometry
-
Humans
-
Lectins / immunology
-
Leukemia, B-Cell / immunology*
-
Leukocyte Common Antigens / immunology
-
Microscopy, Confocal
-
Receptors, IgE / immunology
-
Sialic Acid Binding Ig-like Lectin 2
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antigens, CD19
-
Antigens, CD20
-
Antigens, Differentiation, B-Lymphocyte
-
CD22 protein, human
-
CD40 Antigens
-
CD5 Antigens
-
Cell Adhesion Molecules
-
Drug Carriers
-
Lectins
-
Receptors, IgE
-
Sialic Acid Binding Ig-like Lectin 2
-
Leukocyte Common Antigens